Azacyclic compounds
First Claim
Patent Images
1. A compound of formula (I) wherein Z is in which R is a hydrogen, a cyclic or straight-chained or branched acyclic organyl group, a lower hydroxyalkyl group, a lower aminoalkyl group, or an aralkyl or heteroaralkyl up;
- n is 1;
X1 is methylene, vinylene, or an NH or N(lower alkyl) group; and
X2 is methylene, or, when X1 is methylene or vinylene, X2 is methylene or a bond;
or when X1 is methylene, X2 is O, S, NH, or N(lower alkyl) or a bond;
Y1 is methylene and Y2 is methylene, vinylene, ethylene, propylene, or bond;
or Y1 is a bond and Y2 is vinylene;
or Y1 is ethylene and Y2 is O, S, NH, or N(lower alkyl);
Ar1 and Ar2 independently are unsubstituted or substituted aryl or heteroaryl groups, provided that Ar1 and Ar2 are not simultaneously unsubstituted phenyl; and
W is oxygen;
or a pharmaceutically acceptable salt or prodrug thereof.
4 Assignments
0 Petitions
Accused Products
Abstract
Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.
85 Citations
48 Claims
-
1. A compound of formula (I)
wherein Z is in which R is a hydrogen, a cyclic or straight-chained or branched acyclic organyl group, a lower hydroxyalkyl group, a lower aminoalkyl group, or an aralkyl or heteroaralkyl up; -
n is 1;
X1 is methylene, vinylene, or an NH or N(lower alkyl) group; and
X2 is methylene, or, when X1 is methylene or vinylene, X2 is methylene or a bond;
or when X1 is methylene, X2 is O, S, NH, or N(lower alkyl) or a bond;
Y1 is methylene and Y2 is methylene, vinylene, ethylene, propylene, or bond;
orY1 is a bond and Y2 is vinylene;
orY1 is ethylene and Y2 is O, S, NH, or N(lower alkyl);
Ar1 and Ar2 independently are unsubstituted or substituted aryl or heteroaryl groups, provided that Ar1 and Ar2 are not simultaneously unsubstituted phenyl; and
W is oxygen;
ora pharmaceutically acceptable salt or prodrug thereof. - View Dependent Claims (2, 3, 4, 5, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)
Y1 is methylene and Y2 is a bond, methylene, ethylene, or vinylene; - or
Y1 is ethylene and Y2 is O or S; and
X1 is methylene and X2 is a bond, methylene, O, or S;
orX1 is NH or N(lower alkyl) and X2 is methylene.
-
-
3. A compound according to claim 2, wherein Ar1 and Ar2 independently are mono- or disubstituted phenyl groups.
-
4. A compound according to claim 3, wherein
R is a hydrogen, a lower alkyl group, a cyclic organyl group, or a substituted or unsubstituted aralkyl or heteroaralkyl group; -
n is 1;
Y1 is methylene, Y2 is a bond, methylene, ethylene, or vinylene;
X1 is methylene and X2 is a bond, or, X1 is NH or N(lower alkyl) and X2 is methylene; and
Ar1 and Ar2 are phenyl groups, independently p-substituted with groups selected from lower alkyl, lower alkoxy and halogen.
-
-
5. A compound according to claim 1, having a formula (II)
wherein RN is hydrogen, lower alkyl, aralkyl, or heteroaralkyl; -
ArL is selected from lower alkyl, lower alkoxy and halogen ArR is selected from lower alkyl, lower alkoxy and halogen;
k is 1 or 2 and K is a suitable anion.
-
-
13. A method of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an amount of one or more of the compounds of claim 1 that is effective in inhibiting the activity of the monoamine receptor.
-
14. The method of claim 13 wherein the monoamine receptor is a serotonin receptor.
-
15. The method of claim 14 wherein the serotonin receptor is the 5-HT2A subclass.
-
16. The method of claim 14 wherein the serotonin receptor is in the central nervous system.
-
17. The method of claim 14 wherein the serotonin receptor is in the peripheral nervous system.
-
18. The method of claim 14 wherein the serotonin receptor is in blood cells or platelets.
-
19. The method of claim 14 wherein the serotonin receptor is mutated or modified.
-
20. The method of claim 13 wherein the activity is signaling activity.
-
21. The method of claim 13 wherein the activity is constitutive.
-
22. The method of claim 13 wherein the activity is associated with serotonin receptor activation.
-
23. A method of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an amount of a compound of one or more of the compounds of claim 1 that is effective in inhibiting the activation of the monoamine receptor.
-
24. The method of claim 23 wherein the activation is by an agonistic agent.
-
25. The method of claim 24 wherein the agonistic agent is exogenous.
-
26. The method of claim 24 wherein the agonistic agent is endogenous.
-
27. The method of claim 23 wherein the activation is constitutive.
-
28. The method of claim 23 wherein the monoamine receptor is a serotonin receptor.
-
29. The method of claim 28 wherein the serotonin receptor is the 5-HT2A subclass.
-
30. The method of claim 28 wherein the serotonin receptor is in the central nervous system.
-
31. The method of claim 28 wherein the serotonin receptor is in the peripheral nervous system.
-
32. The method of claim 28 wherein the serotonin receptor is in blood cells or platelets.
-
33. The method of claim 28 wherein the serotonin receptor is mutated or modified.
-
34. A method of treating a disease condition associated with a monoamine receptor comprising administering to a subject in need of such treatment a therapeutically effective amount of one or more of the compounds of claim 1.
-
35. The method of claim 34 wherein the disease condition is selected from the group consisting of schizophrenia, psychosis, migraine, hypertension, thrombosis, vasospasm, ischemia, depression, anxiety, sleep disorders and appetite disorders.
-
36. The method of claim 34 wherein the disease condition is associated with dysfunction of a monoamine receptor.
-
37. The method of claim 34 wherein the disease condition is associated with activation of a monoamine receptor.
-
38. The method of claim 34 wherein the disease condition is associated with increased activity of monoamine receptor.
-
39. The method of claim 34 wherein the monoamine receptor is a serotonin receptor.
-
40. The method of claim 39 wherein the serotonin receptor is the 5- HT2A subclass.
-
41. The method of claim 39 wherein the serotonin receptor is in the central nervous system.
-
42. The method of claim 39 wherein the serotonin receptor is in the peripheral nervous system.
-
43. The method of claim 39 wherein the serotonin receptor is in blood cells or platelets.
-
44. The method of claim 39 wherein the serotonin receptor is mutated or modified.
-
45. A method of treating schizophrenia comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of one or more of the compounds of claim 1.
-
46. A method of treating migraine comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of one or more of the compounds of claim 1.
-
47. A method of treating psychosis comprising administering to subject in need of such treatment a therapeutically effective amount of a compound of one more of the compounds of claim 1.
-
48. A method according to claim 47 wherein the psychosis is a drug-induced psychosis.
-
6. A compound is selected from the group consisting of:
-
N-(1-(1-methylethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-(2,2-dimethylethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-pentylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-hexylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-cyclohexylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-cyclopentylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-cyclobutylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-cyclopropylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-(cyclopentylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-(cyclobutylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-(cyclopropylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-(2-hydroxyethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-(3-hydroxypropyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-((4-methylphenyl)methyl)-N-(piperidin-4-yl)-N′
-phenylmethylcarbamide;
N-((4-methylphenyl)methyl)-N-(1-(2-methylpropyl)piperidin-4-yl)-N′
-phenylmethylcarbamide;
N-(1-((2-bromophenyl)methyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-N′
-phenylmethylcarbamide;
N-(1-((4-hydroxy-3-methoxyphenyl)methyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-N′
-phenylmethylcarbamide;
N-(1-((5-ethylthien-2-yl)methyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-N′
-phenylmethylcarbamide;
N-(1-(imidazol-2-ylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-N′
-phenylmethylcarbamide;
N-(1-(cyclohexylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-N′
-phenylmethylcarbamide;
N-(1-((4-fluorophenyl)methyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-N′
-phenylmethylcarbamide;
N-((4-methylphenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;
N-((4-methylphenyl)methyl)-N-(1-methylpiperidin-4-yl)-4-methoxyphenylacetamide;
N-(1-ethylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-((4-methylphenyl)methyl)-N-(1-propylpiperidin-4-yl)-4-methoxypheylacetamide;
N-(1-butylpiperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-(3,3-dimethylbutyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-(cyclohexylmethyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-((4-methylphenyl)methyl)-N-(1-(2-methytpropyl)piperidin-4-yl)-4-methoxyphenylacetamide;
N-((4-methylphenyl)methyl)-N-(1-((4-methylphenyl)methyl)piperidin-4-yl)-4-methoxyphenylacetamide;
N-(1-((4-hydroxyphenyl)methyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(1-((2-hydroxyphenyl)methyl)piperidin-4-yl)-N-((4-methylphenyl)methyl)-4-methoxyphenylacetamide;
N-(3-phenylpropyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;
N-(2-phenylethyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;
N-((2-methoxyphenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;
N-((2-chlorophenyl)methyl)-N-(piperidin-4-yl)-4methoxyphenylacetamide;
N-((3,4-di-methoxyphenyl)methyl)-N-(piperdin-4-yl)-4-methoxyphenylacetamide;
N-((4-fluorophenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;
N-((2,4-di-chlorophenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;
N-((3-methylphenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;
N-((3-bromophenyl)methyl)-N-(piperidin-4-yl)-4-methoxyphenylacetamide;
N-(1-(phenylmethyl)piperidin-4-yl)-N-(3-phenyl-2-propen-1-yl)-4-methoxyphenylacetamide;
N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-phenylacetamide;
N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-3-phenylpropionamide;
N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-(phenylthio)acetamide;
N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-phenoxyacetamide;
N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-(4-chlorophenoxy)acetamide;
N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-3-methoxyphenylacetamide;
N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-4-fluorophenylacetamide;
N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-2,5-di-methoxyphenylacetamide;
N-((4-methylphenyl)methyl)-N-(1-piperidin-4-yl)-4-chlorophenylacetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-(piperidin-4-yl)acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N(1-methylpiperidin-4-yl) acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-(1-ethylpiperidin-4-yl) acetamide;
2-(4-methoxyphenyl)-N-(4-chlorobenzyl)-N-(1-ethylpiperidin-4-yl)acetamide;
2-(4-methoxyphenyl)-N-(4-chlorobenzyl)-N-(1-isopropylpiperidin-4-yl) acetamide;
2-(4-methoxyphenyl)-N-(4-chlorobenzyl)-N-(piperidin-4-yl)acetamide;
2-(4-methoxyphenyl)-N-(4-chlorobenzyl)-N-(1-cyclopentylpiperidin-4-y) acetamide;
2-(4-methoxyphenyl)-N-(4-chlorobenzyl)-N-(1-isopropylpiperidin-4-yl) acetamide;
2-(phenyl)-N-(4-trifluoromethylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-fluorophenyl)-N-(4-trifluoromethylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Methoxyphenyl)-N-(4-trifluoromethylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Trifluoromethylphenyl)-N-(4-trifluoromethylbenzyl)N-(1-methylpiperidin-4-yl acetamide;
2-(4-Fluorophenyl)-N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Methoxyphenyl)-N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(phenyl)-N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Trifluoromethylphenyl)-N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-trifluoromethylphenyl)-N-[4-(methoxycarbonyl)benzyly]-N-(1-methylpiperidin-4-yl) acetamide;
2-Phenyl-N-[4-(methoxycarbonyl)benzyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Chlorophenyl)-N-[4-(methoxycarbonyl)benzyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Methoxyphenyl)-N-[4-(methoxycarbonyl)benzyl]-N-(1-methylpiperdin-4-yl) acetamide;
2-(4-trifluoromethylphenyl)-N-[4-(methoxycarbonyl)benzyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-Phenyl-N-[4-(methoxycarbonyl)benzyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Chlorophenyl)-N-[4-(methoxycarbonyl)benzyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Methoxyphenyl)-N-[4-(methoxycarbonyl)benzyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-(4 methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(4-chloromethyl-2-thiazolylmethyl) piperidin-4-yl]acetamide;
2-(4 methoxyphenyl)-N-(4-methylbenzyl)-N-{(1-[3(1,3-dihydro-2H-benzimidazol-2-on-1-yl)propyl]piperidin-4-yl}acetamide;
2-(4-methoxyphenyl)-N-(2-4(fluorophenyl)ethyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-methoxyphenyl)-N-[2-(2,5-dimethoxyphenyl)ethyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-methoxyphenyl)-N-[2-(2,4-dichlorophenyl)ethyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-methoxyphenyl)-N-[2-(3-chlorophenyl)ethyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-methoxyphenyl)-N-[2-(3-fluorophenyl)ethyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-ethoxyphenyl)-N-[2-(4-fluorophenethyl]-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-ethoxyphenyl)-N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-{1-[2-(2-hydroxyethoxy)ethyl]piperidin-4-yl}acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-((2-chloro-5-thienyl)methyl)piperidin-4-yl]acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(2-(imidazolidinon-1-yl)ethyl)piperidin-4-yl]acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-{1-[2-(2,4(1H,3H)quinazolinedion-3-yl)ethyl]piperidin-4-yl}acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-{1-[2-(1,3-dioxolan-2-yl)ethyl]piperidin-4-yl}acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-{1-[2-(3-indolyl)ethyl]piperidin-4-yl}acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-{1-[3-(1,2,4-triazol-1-yl)propyl]piperidin-4-yl}acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(5-benzofurazanylmethyl)piperidin-4-yl]acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(5-chlorobenzo[b]thien-3-ylmethyl) piperidin-4-yl]acetamide;
2-(4-methoxyphenyl)-N-(4-methylbenzyl)-N-[1-(5-phenyl-1,2,4-oxadiazol-3-ylmethyl)piperidin-4-yl]acetamide;
2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-isopropylpiperidin-4-yl) acetamide;
2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-ethylpiperidin-4-yl)-acetamide;
2-Phenyl-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide[,2(4-(Chlorophenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide];
2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;
2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-cyclopentylpiperidin-4-yl)-acetamide;
2-(4-Fluorophenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;
2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-(2-hydroxyethyl)-piperidin-4-yl)-acetamide;
2-(4-Chlorophenyl)-N-(4-methylbenzyl)-N-(1-cyclobutylpiperidin-4-yl)-acetamide;
2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-(1-cyclobutylpiperidin-4-yl)-acetamide(,2(4-Methoxyphenyl)-N-(methylbenzyl)-N-(tropin-4-yl)-acetamide];
N-(4-Methylbenzyl)-N-(4-methylpiperidin-4-yl)-N′
-benzyl-carbamide;
N-(4-Methylbenzyl)-N-(1-methylpiperidin-4-yl)-N′
-phenyl-carbamide;
N-Phenethyl-N-(1-methylpiperidin-4-yl)-N′
-benzyl-carbamide;
2-Phenyl-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;
2-(4-Trifluoromethylphenyl)-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;
2-(4-Fluorophenyl)-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;
2-(4-Methoxyphenyl)-N-(4-methoxybenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;
2-(4-Methylphenyl)-N-(4-chlorobenzyl)-N-(1-methylpiperidin-4-yl)-acetamide;
2-(4-Hydroxyphenyl)-N-(4-methylbenzyl)-N(1-methylpiperidin-4-yl)-acetamide;
N-Phenethyl-N-(1-methylpiperidin-4-yl)-N′
-phenyl-carbamide;
N-(3-Phenylpropyl)-N-(1-methylpiperidin-4-yl)-N′
-benzyl-carbamide;
N-(3-Phenylpropyl)-N-(1-methylpiperidin-4-yl)-N′
-phenyl-carbamide;
2-(4-Methoxyphenyl)-2,2-ethylene-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Methoxyphenyl)-N-alpha-methylbenzyl-N-(1-methylpiperidin-4-yl) acetamide;
[2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-(3-tropen-4-yl) acetamide;
]2-Phenyl-2-ethyl-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
N-Phenethyl-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl)-amine;
2-(4-Methoxyphenyl)-N-(1-indanyl)-N-(1-methylpiperidin-4-yl) acetamide;
N-(4-Methylbenzyl)-N-(1-methylpiperidin-4-yl)-N′
-(4-methoxybenzyl)-carbamide;
2-(3,4-dimethoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(3,4-Methylenedioxyphenyl)-N-(4-methylbenzyl)N(1-methylpiperidin-4-yl) acetamide;
2-(4-Methoxyphenyl)-N-(4-methylbenzyl)-N-(1-t-butylpiperidin-4-yl)-acetamide;
N-(4-Methylbenzyl)-N-(1-methylpiperidin-4-yl)-N′
-phenethyl-carbamide;
N-Phenethyl-N-(1-methylpiperidin-4-yl)-N′
-phenethyl-carbamide;
N-(4-Methylbenzyl)-N-(1-t-butylpiperidin-4-yl)-N-(4-methoxybenzyl) carbamide;
2-(4-Ethoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Butoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-i-Propoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-t-Butoxyphenyl)-N-(4-methylbenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Butoxyphenyl)-N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-Propoxyphenyl)-N-(4-flourobenzyl)-N-(1-methylpiperidin-4-yl) acetamide;
2-(4-i-Propoxyphenyl)-N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) acetamide; and
2-(4-t-Butoxyphenyl)-N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl) acetamide.
-
-
7. A compound of formula (I)
wherein Z is in which R is a hydrogen, a cyclic or straight-chained or branched acyclic organyl group, a lower hydroxyalkyl group, a lower aminoalkyl group, or an aralkyl or heteroaralkyl group; - and
n is 1;
X1 is methylene, vinylene, or an NH or N(lower alkyl) group; and
X2 is methylene, or, when X1 is methylene or vinylene, X2 is methylene or a bond;
or when X1 is methylene, X2 is O, S, NH, or N(lower alkyl) or a bond;
Y1 is methylene and Y2 is methylene, vinylene, ethylene, propylene, or bond;
orY1 is a bond and Y2 is vinylene;
orY1 is ethylene and Y2 is O, S, NH, or N(lower alkyl);
Ar1 and Ar2 are different unsubstituted or substituted aryl or heteroaryl groups; and
W is oxygen;
ora pharmaceutically acceptable salt or prodrug thereof. - View Dependent Claims (8, 9, 10, 11)
Y1 is methylene and Y2 is a bond, methylene, ethylene, or vinylene; - or
Y1 is ethylene and Y2 is O or S; and
X1 is methylene and X2 is a bond, methylene, O, or S;
orX1 is NH or N(lower alkyl) and X2 is a methylene.
- and
-
9. A compound according to claim 8, wherein Ar1 and Ar2 independently are mono- or disubstituted phenyl groups.
-
10. A compound according to claim 9, wherein
R is a hydrogen, a lower alkyl group, a cyclic organyl group, or an, optionally substituted, alalkyl or heteroaralkyl group; -
Y1 is methylene, Y2 is a bond, methylene, ethylene, or vinylene;
X1 is methylene and X2 is a bond, or X1 is NH or N(lower alkyl) and X2 is methylene; and
Ar1 and Ar2 are phenyl groups, independently p-substituted with groups selected from alkyl, lower alkoxy and halogen.
-
-
11. A compound according to claim 7, having a formula (II):
-
wherein RN is hydrogen, lower alkyl, aralkyl, or heteroaralkyl;
ArL is selected from lower alkyl, lower alkoxy and halogen ArR is selected from lower alkyl, lower alkoxy and halogen;
k is 1 or 2 and N is a suitable anion.
-
-
12. A pharmaceutical composition comprising an effective amount of a compound of formula (I):
-
wherein Z is in which R is a hydrogen, a cyclic or straight-chained or branched acyclic organyl group, a lower hydroxyalkyl group, a lower aminoalkyl group, or an aralkyl or heteroaralkyl group; and
n is 1;
X1 is methylene, vinylene, or an NH or N(lower alkyl) group; and
X2 is methylene, or, when X1 is methylene or vinylene, X2 is methylene or a bond;
or when X1 is methylene, X2 is O, S, Nil, or N(lower alkyl) or a bond;
Y1 is methylene and Y2 is methylene, vinylene, ethylene, propylene, or bond;
orY1 is a bond and Y2 is vinylene;
orY1 is ethylene and Y2 is O, S, NH, or N(lower alkyl);
Ar1 and Ar2 independently are unsubstituted or substituted aryl or heteroaryl groups, provided that Ar1 and Ar2 are not simultaneously phenyl; and
W is oxygen;
or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable diluent or excipient.
-
Specification